| Business Segments |
Business Segments
The company operates in four primary business segments: North America/Home Medical Equipment (North America/HME), Institutional Products Group (IPG), Europe and Asia/Pacific. The North America/HME segment sells each of the three primary product lines, which includes: lifestyle, mobility and seating, and respiratory therapy products. IPG sells, and rented prior to the disposition of the rentals businesses, long-term care medical equipment, health care furnishings and accessory products. Europe and Asia/Pacific sell product lines similar to North America/HME and IPG. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the company’s consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element.
As of the third quarter of 2016, the company redefined the measure by which it evaluates segment profit or loss. Segment performance is measured and resources are allocated based on a number of factors, with the primary profit or loss measure being segment operating profit (loss). Segment operating profit (loss) represents net sales less cost of products sold less selling general and administrative expenses. Segment operating profit (loss) excludes unallocated corporate general and administrative expenses not allocated to the segments and intersegment sales and profit eliminations, which are included in All Other. In addition, segment operating profit (loss) further excludes charges related to restructuring activities, asset write-downs and gain or loss on sales of businesses (as applicable). The previous performance measure was earnings before income taxes. With the issuance of convertible debt during 2016, this performance measure has not been utilized by the Chief Operating Decision Maker (CODM) as the interest expense incurred by the company is related to the company’s financing decision to issue convertible debt as compared to the operating decisions resulting from allocation of resources and segment operating income performance. In addition, earlier in 2016, the company included an operating income line on the consolidated statement of comprehensive income (loss) to emphasize the CODM’s emphasis on operating income (loss).
As noted, this performance measure, segment operating income (loss), is used by the CODM for purposes of making decisions about allocating resources to a segment and assessing its performance. In addition, this metric is reviewed by the company’s Board of Directors regarding segment performance and is a key metric in the performance management assessment of the company's employees.
The information by segment is as follows (in thousands): | | | | | | | | | | | | | | 2016 | | 2015 | | 2014 | Revenues from external customers | | | | | | North America/HME | $ | 397,702 |
| | $ | 474,196 |
| | $ | 507,867 |
| Institutional Products Group | 64,413 |
| | 87,137 |
| | 102,796 |
| Europe | 540,013 |
| | 536,463 |
| | 610,555 |
| Asia/Pacific | 45,346 |
| | 44,542 |
| | 48,945 |
| Consolidated | $ | 1,047,474 |
| | $ | 1,142,338 |
| | $ | 1,270,163 |
| Intersegment revenues | | | | | | North America/HME | $ | 100,793 |
| | $ | 111,321 |
| | $ | 84,247 |
| Institutional Products Group | 2,885 |
| | 997 |
| | 6,711 |
| Europe | 10,139 |
| | 9,958 |
| | 8,938 |
| Asia/Pacific | 19,366 |
| | 20,661 |
| | 26,173 |
| Consolidated | $ | 133,183 |
| | $ | 142,937 |
| | $ | 126,069 |
| Depreciation and amortization | | | | | | North America/HME (1) | $ | 5,932 |
| | $ | 7,549 |
| | $ | 9,077 |
| Institutional Products Group | 254 |
| | 1,980 |
| | 7,656 |
| Europe | 7,062 |
| | 7,183 |
| | 11,111 |
| Asia/Pacific | 1,349 |
| | 1,463 |
| | 2,406 |
| All Other (2) | 38 |
| | 29 |
| | 173 |
| Discontinued Operations | — |
| | — |
| | 518 |
| Consolidated (1) | $ | 14,635 |
| | $ | 18,204 |
| | $ | 30,941 |
| | | | | | |
| | | | | | | | | | | | | | 2016 | | 2015 | | 2014 | Net interest expense (income) | | | | | | North America/HME (1) | $ | 15,119 |
| | $ | 3,305 |
| | $ | 2,196 |
| Institutional Products Group | 191 |
| | 1,028 |
| | 2,244 |
| Europe | 197 |
| | (444 | ) | | (209 | ) | Asia/Pacific | 103 |
| | 82 |
| | 149 |
| Consolidated (1) | $ | 15,610 |
| | $ | 3,971 |
| | $ | 4,380 |
| Operating income (loss) | | | | | | North America/HME | $ | (37,748 | ) | | $ | (29,245 | ) | | $ | (59,124 | ) | Institutional Products Group | 5,693 |
| | 7,834 |
| | 6,248 |
| Europe | 33,994 |
| | 39,794 |
| | 50,169 |
| Asia/Pacific | (1,436 | ) | | (3,493 | ) | | (7,463 | ) | All Other (2) | (20,657 | ) | | (20,712 | ) | | (24,507 | ) | Charge related to restructuring activities | (2,447 | ) | | (1,971 | ) | | (11,112 | ) | Gains on sales of businesses | 7,386 |
| | 24 |
| | — |
| Asset write-off (3) | — |
| | — |
| | (13,041 | ) | Consolidated operating loss | (15,215 | ) | | (7,769 | ) | | (58,830 | ) | Net gain on convertible derivatives | 1,268 |
| | — |
| | — |
| Net Interest expense | (15,610 | ) | | (3,971 | ) | | (4,380 | ) | Loss from continuing operations before income taxes | $ | (29,557 | ) | | $ | (11,740 | ) | | $ | (63,210 | ) | Assets | | | | | | North America/HME (4) | $ | 261,538 |
| | $ | 203,851 |
| | $ | 209,122 |
| Institutional Products Group (5) | 38,657 |
| | 38,730 |
| | 42,692 |
| Europe | 575,981 |
| | 557,740 |
| | 638,896 |
| Asia/Pacific | 25,703 |
| | 24,421 |
| | 30,231 |
| All Other (2) | 1,864 |
| | 1,752 |
| | 15,647 |
| Assets Held for Sale (4) (5) | — |
| | 11,649 |
| | 27,143 |
| Consolidated | $ | 903,743 |
| | $ | 838,143 |
| | $ | 963,731 |
| Long-lived assets | | | | | | North America/HME (4) | $ | 70,553 |
| | $ | 49,141 |
| | $ | 44,727 |
| Institutional Products Group (3) | 30,603 |
| | 30,278 |
| | 33,487 |
| Europe | 388,724 |
| | 391,533 |
| | 459,957 |
| Asia/Pacific | 2,927 |
| | 3,140 |
| | 4,046 |
| All Other (2) | 1,864 |
| | 1,752 |
| | 15,527 |
| Consolidated | $ | 494,671 |
| | $ | 475,844 |
| | $ | 557,744 |
| Expenditures for assets | | | | | | North America/HME | $ | 3,398 |
| | $ | 1,232 |
| | $ | 2,960 |
| Institutional Products Group | 58 |
| | 212 |
| | 1,232 |
| Europe | 5,580 |
| | 5,058 |
| | 6,708 |
| Asia/Pacific | 1,115 |
| | 969 |
| | 1,417 |
| All Other (2) | — |
| | 51 |
| | — |
| Discontinued Operations | — |
| | — |
| | 10 |
| Consolidated | $ | 10,151 |
| | $ | 7,522 |
| | $ | 12,327 |
|
________________________ | | (1) | Restated 2015 and 2014 for reclass of debt fees from depreciation and amortization to net interest expense with adoption of ASU 2015-03. |
| | (2) | Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments, and gain or loss on convertible debt derivatives. |
| | (3) | Intangible asset impairment related to the rentals businesses which were included in the Institutional Products Group segment. |
| | (4) | Restated 2015 and 2014 for GCM sale on September 30, 2016 and classified as assets held for sale. |
| | (5) | Restated 2014 for rentals businesses sold in July 2015 and classified as assets held for sale. |
Net sales by product, are as follows (in thousands): | | | | | | | | | | | | | | 2016 | | 2015 | | 2014 | North America/HME | | | | | | Lifestyle Products | $ | 173,301 |
| | $ | 222,944 |
| | $ | 239,625 |
| Mobility and Seating | 116,722 |
| | 117,232 |
| | 115,776 |
| Respiratory Therapy | 104,631 |
| | 130,349 |
| | 149,063 |
| Other(1) | 3,048 |
| | 3,671 |
| | 3,403 |
|
| $ | 397,702 |
| | $ | 474,196 |
| | $ | 507,867 |
| Institutional Products Group | | | | | | Continuing Care | $ | 64,413 |
| | $ | 87,137 |
| | $ | 102,796 |
| | | | | | | Europe | | | | | | Lifestyle Products | $ | 274,684 |
| | $ | 275,932 |
| | $ | 322,370 |
| Mobility and Seating | 214,713 |
| | 208,730 |
| | 228,163 |
| Respiratory Therapy | 35,030 |
| | 36,373 |
| | 40,661 |
| Other(1) | 15,586 |
| | 15,428 |
| | 19,361 |
|
| $ | 540,013 |
| | $ | 536,463 |
| | $ | 610,555 |
| Asia/Pacific | | | | | | Mobility and Seating | $ | 25,254 |
| | $ | 25,655 |
| | $ | 28,174 |
| Lifestyle Products | 10,161 |
| | 10,277 |
| | 11,772 |
| Continuing Care | 3,521 |
| | 3,115 |
| | 3,956 |
| Respiratory Therapy | 1,244 |
| | 807 |
| | 1,286 |
| Other(1) | 5,166 |
| | 4,688 |
| | 3,757 |
| | $ | 45,346 |
| | $ | 44,542 |
| | $ | 48,945 |
| | | | | | | Total Consolidated | $ | 1,047,474 |
| | $ | 1,142,338 |
| | $ | 1,270,163 |
|
________________________ | | (1) | Includes various services, including repair services, equipment rentals and external contracting. |
No single customer accounted for more than 3.4% of the company’s sales.
|